Should I buy or sell Roivant Sciences stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks .

What is Roivant Sciences' stock price target for 2024?

10 Wall Street analysts have issued 1-year target prices for Roivant Sciences' stock. Their ROIV share price targets range from $12.00 to $23.00. On average, they anticipate the company's share price to reach $16.90 in the next year. This suggests a possible upside of 61.6% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts .

How have ROIV shares performed in 2024?

Roivant Sciences' stock was trading at $11.23 on January 1st, 2024. Since then, ROIV shares have decreased by 6.9% and is now trading at $10.46. View the best growth stocks for 2024 here .

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our ROIV earnings forecast .

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. The company earned $37.14 million during the quarter, compared to analysts' expectations of $30.72 million. Roivant Sciences had a negative trailing twelve-month return on equity of 33.38% and a net margin of 3,624.14%.

What ETFs hold Roivant Sciences' stock?

ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) , Virtus LifeSci Biotech Products ETF (BBP) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Invesco Nasdaq Biotechnology ETF (IBBQ) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ProShares Ultra Nasdaq Biotechnology (BIB) . iShares Biotechnology ETF (IBB) .

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Edge Wealth Management LLC (0.01%), State of Michigan Retirement System (0.01%), Allspring Global Investments Holdings LLC (0.01%) and State of Alaska Department of Revenue (0.00%). Insiders that own company stock include Eric Venker , Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar , Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends .

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ROIV Stock Alerts

$10.46

+0.10 (+0.97%)

(As of 04/19/2024 ET)

Compare

Today's Range: $10.27
▼
$10.48
50-Day Range: $9.87
▼
$11.80
52-Week Range: $8.06
▼
$13.24

Volume: 4.66 million shs
Average Volume: 6.91 million shs
Market Capitalization: $8.43 billion

P/E Ratio: 2.01
Dividend Yield: N/A
Price Target: $16.90

Get Roivant Sciences alerts:

Roivant Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 61.6% Upside
$16.90 Price Target
Short Interest: Bearish
5.59% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.36) to ($1.35) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

299th out of 911 stocks

Pharmaceutical Preparations Industry

127th out of 411 stocks

4.5

Analyst's Opinion

Consensus Rating
Roivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Roivant Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
5.59% of the float of Roivant Sciences has been sold short.
Short Interest Ratio / Days to Cover
Roivant Sciences has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Roivant Sciences has recently decreased by 2.03%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Roivant Sciences does not currently pay a dividend.
Dividend Growth
Roivant Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ROIV.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Roivant Sciences this week, compared to 6 articles on an average week.
Search Interest
13 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.
MarketBeat Follows
Only 12 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,058,694.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Roivant Sciences is held by insiders.
Percentage Held by Institutions
64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Roivant Sciences are expected to grow in the coming year, from ($1.36) to ($1.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Roivant Sciences is 2.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.09.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roivant Sciences is 2.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 227.14.
Price to Book Value per Share Ratio
Roivant Sciences has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Roivant Sciences Stock (NASDAQ:ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ROIV Stock News Headlines

April 14, 2024 | markets.businessinsider.com

Sunrun (RUN) Gets a Buy from RBC Capital

April 4, 2024 | msn.com

Roivant's anti-inflammatory drug shows promise in mid-stage study

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 2, 2024 | msn.com

Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study

April 2, 2024 | reuters.com

Roivant's anti-inflammatory drug succeeds in mid-stage study

April 2, 2024 | globenewswire.com

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

April 1, 2024 | msn.com

Compare with CoinDesk Market Index (CDICMI)

March 26, 2024 | msn.com

Viking Therapeutics gains on early data for oral weight loss therapy

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

March 26, 2024 | msn.com

'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter group

March 14, 2024 | fr.investing.com

L'objectif de cours de Roivant Sciences relevé à 16$ par Goldman Sachs

March 13, 2024 | edition.cnn.com

Travere Therapeutics, Inc.

March 13, 2024 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)

February 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Roivant Sciences: Undervaluation and Promising Pipeline Drive Positive Outlook

February 15, 2024 | finance.yahoo.com

Do You Think the Management of Roivant Sciences (ROIV) Can Create Value?

February 14, 2024 | msn.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2023 Earnings Call Transcript

February 14, 2024 | markets.businessinsider.com

Hold Rating on Roivant Sciences Amidst Mixed Performance and Strategic Focus

February 14, 2024 | markets.businessinsider.com

The Analyst Landscape: 4 Takes On Roivant Sciences

February 14, 2024 | finance.yahoo.com

Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations

February 14, 2024 | markets.businessinsider.com

Buy Rating for Roivant Sciences: Solid Sales and Promising Clinical Developments

February 14, 2024 | realmoney.thestreet.com

Roivant Sciences price target lowered by $2 at Goldman Sachs, here's why

February 14, 2024 | finance.yahoo.com

Q3 2024 Roivant Sciences Ltd Earnings Call

February 13, 2024 | finance.yahoo.com

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

February 12, 2024 | msn.com

Roivant Sciences Q3 2024 Earnings Preview

February 10, 2024 | finance.yahoo.com

Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares

February 1, 2024 | marketwatch.com

Roche Expected to Report Lower Sales, Profit -- Earnings Preview

January 30, 2024 | finance.yahoo.com

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

See More Headlines

Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 6/26/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ROIV
CUSIP: N/A
CIK: 1635088
Web: roivant.com
Phone: 44-20-7400-3347
Fax: N/A
Employees: 904
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.90
High Stock Price Target: $23.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +63.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $5.20
Trailing P/E Ratio: 1.98
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,009,030,000.00
Net Margins: 3,624.14%
Pretax Margin: 3,461.24%
Return on Equity: -33.38%
Return on Assets: -26.06%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 27.79
Quick Ratio: 27.79

Sales & Book Value

Annual Sales: $61.28 million
Price / Sales: 135.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.11 per share
Price / Book: 4.89

Miscellaneous

Outstanding Shares: 805,850,000
Free Float: 768,777,000
Market Cap: $8.32 billion
Optionable: Optionable
Beta: 1.34

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Matthew Gline (Age 40)
CEO & Director
Comp: $1.77M
Dr. Eric Venker M.D. (Age 37)
Pharm.D., President & COO
Comp: $1.28M
Dr. Mayukh Sukhatme M.D. (Age 48)
President, Chief Investment Officer & Director
Comp: $1.72M
Mr. Richard Pulik (Age 45)
Chief Financial Officer
Ms. Rakhi Kumar (Age 44)
Chief Accounting Officer
Dr. Huafeng Xu Ph.D.
Chief Technology Officer
Mr. Jo Chen
General Counsel
Ms. Kelly Graff
Head of People
Ms. Marianne L. Romeo (Age 56)
Head of Global Transactions & Risk Management
Mr. Alex Gasner
Executive Vice President of Roivant Health

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ROIV Stock Analysis - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings or view top-rated stocks.
What is Roivant Sciences' stock price target for 2024?: 10 Wall Street analysts have issued 1-year target prices for Roivant Sciences' stock. Their ROIV share price targets range from $12.00 to $23.00. On average, they anticipate the company's share price to reach $16.90 in the next year. This suggests a possible upside of 61.6% from the stock's current price.
View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts.
How have ROIV shares performed in 2024?: Roivant Sciences' stock was trading at $11.23 on January 1st, 2024. Since then, ROIV shares have decreased by 6.9% and is now trading at $10.46.
View the best growth stocks for 2024 here.
When is Roivant Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our ROIV earnings forecast.

How were Roivant Sciences' earnings last quarter?: Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. The company earned $37.14 million during the quarter, compared to analysts' expectations of $30.72 million. Roivant Sciences had a negative trailing twelve-month return on equity of 33.38% and a net margin of 3,624.14%.
What ETFs hold Roivant Sciences' stock?: ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ProShares Ultra Nasdaq Biotechnology (BIB).iShares Biotechnology ETF (IBB).
Who are Roivant Sciences' major shareholders?: Roivant Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Edge Wealth Management LLC (0.01%), State of Michigan Retirement System (0.01%), Allspring Global Investments Holdings LLC (0.01%) and State of Alaska Department of Revenue (0.00%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends.
How do I buy shares of Roivant Sciences?: Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ROIV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Roivant Sciences (ROIV) Stock Price, News & Analysis

Roivant Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Roivant Sciences Stock (NASDAQ:ROIV)

ROIV Stock Price History

ROIV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ROIV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™